Exhibit 99.2  Gemini Therapeutics Debuts as Publicly Traded Precision Medicine Company Focused on Age-Related Macular Degeneration

- Business combination transaction with FS Development Corp., a special purpose acquisition company sponsored by Foresite Capital, completed on February 5, 2021 -

This is the opening of the release as filed. Read the full document on SEC.gov, or read it in full on SPAC Watch with the trust, deadline and warrant terms alongside it.